English Version

For a 50+ year-old woman diagnosed with Guillain-Barré Syndrome (GBS), possibly following a COVID-19 infection or the BioNTech vaccine, the treatment options primarily focus on immunotherapy to manage symptoms and promote recovery. Here are the recommended treatment approaches:

Primary Treatments

• Intravenous Immunoglobulin (IVIg): This therapy involves administering immunoglobulin derived from blood donors, which helps reduce the immune system's attack on the nervous system. It is typically given at a dosage of 0.4 g/kg daily for five consecutive days and is effective in hastening recovery in many patients¹²³.
• Plasmapheresis: Also known as plasma exchange, this procedure removes the liquid part of blood (plasma) that contains harmful antibodies. It can be an alternative to IVIg, especially for patients who do not respond adequately to IVIg therapy. Plasmapheresis is usually performed in a series of treatments over several days¹⁴².

Both treatments are most effective when initiated early in the course of the disease, ideally within the first few weeks after symptom onset³⁵.

Supportive Care

In addition to immunotherapy, supportive care is crucial for managing symptoms and preventing complications:

• Monitoring and Management: Continuous monitoring of respiratory function, blood pressure, and heart rate is essential. Patients may require assistance with mobility and daily activities as they may experience significant weakness or paralysis¹⁶.
• Physical Therapy: Rehabilitation through physical therapy helps maintain muscle strength and joint mobility. Early intervention can prevent complications such as muscle atrophy and joint contractures⁶.
• Nutritional Support: If swallowing difficulties arise, enteral feeding via a nasogastric tube or a PEG (percutaneous endoscopic gastrostomy) may be necessary to ensure adequate nutrition⁶.
• Psychological Support: Patients often experience anxiety due to their condition; therefore, psychological support and clear communication about their treatment and prognosis are important⁶.

Considerations for Future Treatments

Research is ongoing to explore novel immunomodulatory therapies for GBS, particularly for patients who do not respond to standard treatments. These may include drugs targeting specific immune mechanisms involved in GBS pathogenesis⁴⁵.

In summary, while there is no known cure for GBS, early intervention with IVIg or plasmapheresis combined with comprehensive supportive care can significantly improve outcomes for affected individuals.